<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <title>Innohep® Syringes/Vials - Patient Information</title>
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <!-- Import Google Fonts -->
    <link href="https://fonts.googleapis.com/css2?family=Poppins:wght@400;700&display=swap" rel="stylesheet">
    <style>
        /* CSS Styling */
        :root {
            /* Brand Colors */
            --spring-green: #8cb811;
            --midnight-blue: #19475d;
            --black: #00131d;
            --white: #ffffff;
            /* Text Colors */
            --primary-text-color: var(--black);
            --secondary-text-color: var(--black-70);
            /* Background Colors */
            --background-color: var(--white);
        }

        /* General Styles */
        body {
            margin: 0;
            font-family: 'Poppins', sans-serif;
            color: var(--primary-text-color);
            background-color: var(--background-color);
        }

        a {
            text-decoration: none;
            color: inherit;
        }

        /* Header Styles */
        header {
            display: flex;
            justify-content: space-between;
            align-items: center;
            background-color: var(--black);
            padding: 0 20px;
            position: sticky;
            top: 0;
            z-index: 100;
        }

        .logo img {
            height: 50px;
        }

        .nav-links {
            list-style: none;
            display: flex;
            flex-direction: row;
        }

        .nav-links li {
            margin: 0 15px;
        }

        .nav-links a {
            color: var(--white);
            font-weight: bold;
            font-size: 18px;
        }

        /* Burger Menu (Mobile) */
        .burger {
            display: none;
            cursor: pointer;
        }

        .burger div {
            width: 25px;
            height: 3px;
            background-color: var(--white);
            margin: 5px;
        }

        /* Hero Section */
        .hero {
            text-align: center;
            padding: 100px 20px;
            background-color: var(--spring-green);
            color: var(--white);
        }

        .hero h1 {
            font-size: 60px;
            line-height: 70px;
            font-weight: bold;
        }

        .hero p {
            font-size: 25px;
            line-height: 35px;
        }

        /* Content Sections */
        .content-section {
            padding: 60px 20px;
            max-width: 800px;
            margin: 0 auto;
        }

        .content-section h2 {
            color: var(--midnight-blue);
            margin-bottom: 20px;
            font-size: 40px;
            line-height: 50px;
            font-weight: bold;
        }

        .content-section p,
        .content-section ul {
            font-size: 18px;
            line-height: 28px;
            color: var(--secondary-text-color);
        }

        .content-section ul {
            list-style-type: disc;
            margin-left: 40px;
        }

        .content-section li {
            margin-bottom: 10px;
        }

        /* Footer */
        footer {
            text-align: center;
            padding: 20px;
            background-color: var(--black);
            color: var(--white);
            font-size: 18px;
            line-height: 22px;
        }

        /* Responsive Styles */
        @media screen and (max-width: 768px) {
            .nav-links {
                display: none;
                flex-direction: column;
                width: 100%;
                position: absolute;
                top: 70px;
                left: 0;
                background-color: var(--black);
            }

            .nav-links li {
                margin: 15px 0;
                text-align: center;
            }

            .burger {
                display: block;
            }

            .hero {
                padding: 60px 20px;
            }

            .hero h1 {
                font-size: 40px;
                line-height: 50px;
            }

            .hero p {
                font-size: 20px;
                line-height: 30px;
            }

            .content-section h2 {
                font-size: 30px;
                line-height: 40px;
            }

            .content-section p,
            .content-section ul {
                font-size: 16px;
                line-height: 24px;
            }
        }
    </style>
</head>
<body>
    <!-- Header -->
    <header>
        <div class="logo">
            <!-- Placeholder Image -->
            <img src="https://via.placeholder.com/150" alt="Innohep Logo">
        </div>
        <nav>
            <ul class="nav-links">
                <li><a href="#formulations">Formulations</a></li>
                <li><a href="#properties">Properties</a></li>
                <li><a href="#indications">Indications</a></li>
                <li><a href="#dosage">Dosage</a></li>
                <li><a href="#special-considerations">Special Considerations</a></li>
                <li><a href="#adverse-effects">Adverse Effects</a></li>
                <li><a href="#contraindications">Contraindications</a></li>
                <li><a href="#interactions">Interactions</a></li>
                <li><a href="#pregnancy-lactation">Pregnancy & Lactation</a></li>
                <li><a href="#storage">Storage</a></li>
                <li><a href="#instructions">Instructions for Injection</a></li>
            </ul>
            <div class="burger">
                <div></div>
                <div></div>
                <div></div>
            </div>
        </nav>
    </header>

    <!-- Main Content -->
    <main>
        <!-- Hero Section -->
        <section class="hero">
            <h1>Innohep® Syringes/Vials</h1>
            <p>Anticoagulant Tinzaparin sodium for subcutaneous injection</p>
        </section>

        <!-- Formulations Section -->
        <section id="formulations" class="content-section">
            <h2>Formulations</h2>
            <p><strong>10 Vials of 2 ml:</strong></p>
            <ul>
                <li>Tinzaparin sodium 10,000 IU anti-Xa/ml, preserved with benzyl alcohol (10 mg/ml).</li>
                <li>Tinzaparin sodium 20,000 IU anti-Xa/ml, preserved with benzyl alcohol (10 mg/ml), stabilized with sodium metabisulphite.</li>
            </ul>
            <p><strong>10 Pre-filled syringes with needle safety device:</strong></p>
            <ul>
                <li>Volumes of 0.25ml, 0.35ml, or 0.45ml containing Tinzaparin sodium 10,000 IU anti-Xa/ml.</li>
            </ul>
            <p><strong>2 Pre-filled syringes with needle safety device:</strong></p>
            <ul>
                <li>Volumes of 0.5ml, 0.7ml, or 0.9ml containing Tinzaparin sodium 20,000 IU anti-Xa/ml, stabilized with sodium metabisulphite.</li>
            </ul>
        </section>

        <!-- Properties Section -->
        <section id="properties" class="content-section">
            <h2>Properties</h2>
            <p>Tinzaparin sodium is a low molecular weight heparin produced by enzymatic depolymerization of conventional heparin. Its molecular mass ranges between 1,000 and 14,000 daltons, with a peak maximum at approximately 4,500 daltons. It functions as an anti-thrombotic agent. The bioavailability following subcutaneous injection is approximately 90%, with an absorption half-life of 200 minutes and peak plasma activity within 4–6 hours. The elimination half-life is about 80 minutes, and it is primarily eliminated unchanged in urine.</p>
            <p>The pharmacokinetics/pharmacodynamics are monitored by anti-Xa activity, demonstrating a linear dose-response relationship between plasma activity and the administered dose.</p>
        </section>

        <!-- Indications Section -->
        <section id="indications" class="content-section">
            <h2>Indications</h2>
            <ul>
                <li>Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE).</li>
                <li>Prevention of postoperative DVT in general and orthopaedic surgery.</li>
                <li>Prevention of clotting in in-dwelling intravenous lines during extracorporeal circulation and haemodialysis.</li>
            </ul>
        </section>

        <!-- Dosage Section -->
        <section id="dosage" class="content-section">
            <h2>Dosage</h2>
            <h3>1. Treatment of DVT and PE:</h3>
            <p>
              175 IU anti-Xa/kg body weight subcutaneously once daily.</p>

            <h3>2. Thromboprophylaxis:</h3>
            <p><strong>Moderate risk (general surgery):</strong> 3,500 IU anti-Xa s.c. 2 hours pre-surgery, continued postoperatively once daily for 7–10 days.</p>
            <p><strong>High risk (e.g., total hip replacement):</strong> 4,500 IU anti-Xa s.c. 12 hours pre-surgery or 50 IU anti-Xa/kg s.c. 2 hours pre-surgery and then daily until mobilized.</p>

            <h3>3. Haemodialysis:</h3>
            <p><strong>Short-term (&lt;4 hours):</strong> Bolus dose of 2,000–2,500 IU anti-Xa at the beginning.</p>
            <p><strong>Long-term (&gt;4 hours):</strong> Bolus dose of 2,500 IU anti-Xa followed by an infusion of 750 IU anti-Xa/hour.</p>
        </section>

        <!-- Special Considerations Section -->
        <section id="special-considerations" class="content-section">
            <h2>Special Considerations</h2>
            <p><strong>Elderly:</strong> Renal function assessment recommended (e.g., Cockcroft-Gault formula). No dose reduction needed with normal renal function.</p>
            <p><strong>Renal Impairment:</strong> Caution for severe impairment (creatinine clearance &lt;30 ml/min).</p>
            <p><strong>Overdose:</strong> An overdose may lead to hemorrhage. The antidote is protamine sulphate (1 mg neutralizes 100 IU anti-Xa of tinzaparin).</p>
        </section>

        <!-- Adverse Effects Section -->
        <section id="adverse-effects" class="content-section">
            <h2>Adverse Effects</h2>
            <p>Safe when used at recommended doses. Risks include bleeding, priapism, and skin necrosis.</p>
        </section>

        <!-- Contraindications Section -->
        <section id="contraindications" class="content-section">
            <h2>Contraindications</h2>
            <p>Hypersensitivity, severe uncontrolled hypertension, acute cerebral insults, and septic endocarditis.</p>
        </section>

        <!-- Interactions Section -->
        <section id="interactions" class="content-section">
            <h2>Interactions</h2>
            <p>Concomitant use with drugs affecting haemostasis may enhance effects.</p>
        </section>

        <!-- Pregnancy and Lactation Section -->
        <section id="pregnancy-lactation" class="content-section">
            <h2>Pregnancy and Lactation</h2>
            <p>Limited data; use caution, particularly with prosthetic heart valves.</p>
        </section>

        <!-- Storage Section -->
        <section id="storage" class="content-section">
            <h2>Storage</h2>
            <p>Do not store above 30°C.</p>
            <p><strong>Shelf life:</strong> Vials – 2 years, Syringes – 3 years.</p>
        </section>

        <!-- Instructions for Injection Section -->
        <section id="instructions" class="content-section">
            <h2>Instructions for Injection</h2>
            <p>Detailed instructions on preparing, injecting, and disposing of syringes are included.</p>
            <p><em>Last Revised: October 2015</em></p>
        </section>
    </main>

    <!-- Footer -->
    <footer>
        <p>&copy; 2023 Innohep. All rights reserved.</p>
    </footer>

    <!-- Inline JavaScript -->
    <script>
        // Mobile Navigation Toggle
        const burger = document.querySelector('.burger');
        const nav = document.querySelector('.nav-links');

        burger.addEventListener('click', () => {
            nav.classList.toggle('nav-active');
        });
    </script>
</body>
</html>
